Search Results for “artificial intelligence” – Page 10 – media

GSK, Flagship Pioneering Commit $150M to Start R&D Pact for Novel Drugs and Vaccines

Respiratory disease and immunology are the initial focus areas of GSK’s new drug discovery partnership with Flagship Pioneering. A similar Flagship alliance with Pfizer recently announced it is pursuing novel obesity treatments. By Frank VinluanGSK already has a strong presence in respiratory disease and immunology, two of its core therapeutic areas. The pharmaceutical giant is now teaming up with Flagship Pioneering in an alliance intended to discover novel medicines to bolster its pipelines in both disease categories. The deal announced Monday calls for the partners to fund up to $150 million up front for an exploration phase intended to identify concepts that can leverage the technologies of Flagship’s portfolio companies. Flagship forms and incubates startups, each one based on a platform technology that focuses on some aspect of biology. The research stemming from these platforms informs the discovery and development of novel medicines. The best known of these “bioplatform” companies ...
- Source: drugdu
- 110
- July 31, 2024
study

Dive Brief A recent study showed that a version of ChatGPT analyzes medical images at an expert level but frequently reached the right answer with incorrect reasoning. The results, which were published Tuesday in the peer-reviewed journal npj Digital Medicine, show OpenAI’s artificial intelligence GPT-4 with vision is as good at answering multiple-choice questions about medical images as physicians who lack access to external resources. However, the model made mistakes in image comprehension, while still reaching the right answer, 27% of the time. The researchers said the errors show the need for further study before the AI models are integrated into clinical workflows. Dive Insigh GPT-4 with vision, called GPT-4V, is a version of the ChatGPT large language model that can analyze images and text at the same time. Pilot medical studies found the model outperformed medical students and physicians in closed-book settings. However, those studies looked at the answers ...
- Source: drugdu
- 78
- July 29, 2024
AI Model Identifies Breast Tumor Stages Likely To Progress to Invasive Cancer

Ductal carcinoma in situ (DCIS) is a non-invasive type of tumor that can sometimes progress to a more lethal form of breast cancer and represents about 25% of all breast cancer cases. Between 30% and 50% of DCIS patients may develop an invasive stage of cancer, yet identifying which tumors will progress is still a challenge due to unknown biomarkers. Current diagnostic practices include multiplexed staining or single-cell RNA sequencing to determine DCIS stages in tissue samples, but these methods are costly and not widely used. This has led to potential overtreatment of patients with DCIS. Now, a new artificial intelligence (AI) model can distinguish different stages of DCIS from inexpensive and readily available breast tissue images. The model developed by an interdisciplinary team of researchers from MIT (Cambridge, MA, USA) and ETH Zurich (Zurich, Switzerland) was trained and tested using one of the largest datasets of its kind ...
- Source: https://www.labmedica.com/pathology/articles/294801919/ai-model-identifies-breast-tumor-stages-likely-to-progress-to-invasive-cancer.html
- 69
- July 26, 2024
【EXPERT Q&A】What are the potential areas for improvement in the accuracy of medical equipment?

Drugdu.com expert’s response: The potential for improvement in the accuracy of medical equipment primarily manifests in the following aspects: I.Technological Advancement and Innovation 1.Genetic Testing and Analysis: By leveraging advanced genomic technologies, patient genetic information can be analyzed with greater precision, providing data support for the customization of personalized medical devices. This precise data analysis facilitates the devices’ better adaptation to individual patient differences. 2.Personalized Drug Delivery Systems: Developing delivery systems capable of precisely adjusting drug dosage and release rates based on patients’ genetic profiles and physiological states ensures the drugs’ effectiveness and safety within the body. 3.3D Printing Technology: Utilizing 3D printing to create patient-specific surgical models and prosthetics enhances surgical precision and personalization. For instance, printing prosthetics that perfectly match patients’ anatomical structures reduces surgical risks and improves recovery outcomes. 4.Real-time Physiological Monitoring: Developing medical devices capable of continuously and accurately monitoring patients’ physiological states, such as wearable ...
- Source: drugdu
- 90
- July 19, 2024
AI Identifies Drug-Resistant Typhoid-Like Infection from Microscopy Images within Hours

Antimicrobial resistance is becoming a serious global health concern, making many infections increasingly difficult to treat and limiting available treatment options. This escalation in resistance raises the concern of some infections soon becoming untreatable. A major challenge for healthcare providers is quickly distinguishing between organisms that respond to standard first-line drugs and those that are resistant. Traditional testing methods, which involve culturing bacteria, testing them against various antimicrobial agents, and either manual or machine analysis, can take several days. This delay often leads to the administration of ineffective drugs, which can cause more severe health issues and potentially contribute to the development of further drug resistance. Researchers have now demonstrated that artificial intelligence (AI) can significantly cut down the time needed to accurately diagnose drug-resistant infections. They have developed an algorithm capable of correctly identifying drug-resistant bacteria from microscopy images alone. In research published in Nature Communications, the team of ...
- Source: drugdu
- 76
- July 18, 2024
Innovate UK grants £4m to four companies to evaluate biomarkers for dementia

The progressive neurodegenerative disease affects more than 55 million people globally Innovate UK has awarded £4m through its Contracts for Innovation to four UK companies for research into dementia diagnosis. As part of the Bio-Hermes-002 study led by the US-based Global Alzheimer’s Platform Foundation (GAP) in partnership with Novo Nordisk, the organisations will evaluate blood-based and digital innovative biomarkers for the neurological condition. Affecting more than 55 million people globally, which is expected to triple by 2050, dementia is a neurodegenerative condition that affects the ability to remember, think or make decisions in everyday life. The study aims to explore whether these biomarkers can predict the extent of tau and amyloid brain pathology and potentially provide more efficient and less invasive alternatives to the current gold standard for dementia diagnoses: positron emission tomography brain imaging. The project will involve 1,000 participants who are cognitively normal, have mild cognitive impairment or ...
- Source: https://www.ukri.org/news/uk-and-us-join-forces-to-tackle-dementia-with-innovative-biomarkers/
- 92
- July 17, 2024
UK DRI and NHS collaborate on digitally enabled dementia care platform

by Jen Brogan | 10th Jul 2024 | News Around one in five dementia hospitalisations are due to potentially preventable causes The UK Dementia Research Institute (UK DRI), in collaboration with the NHS, aims to conduct a new two-year study to prepare its digitally-enabled dementia care platform, Minder, to be integrated into health and social care services. Funded by LifeArc, the study will enable digital care for people living with dementia while empowering the NHS and social care services to provide care of the highest quality in patients’ own homes. Estimated to affect 944,000 people in the UK, dementia is a general term for the impaired ability to remember, think, or make decisions that affects everyday life. Developed by the UK DRI Centre for Care Research and Technology, Minder is a home monitoring platform that harnesses artificial intelligence (AI) and digital technology and is integrated with public services to detect ...
- Source: drugdu
- 78
- July 12, 2024
Novel AI-Based Analysis Method Uncovers New Insight into ALS Progression

Amyotrophic Lateral Sclerosis (ALS) is a fatal condition where motor neurons, which are crucial for controlling movement, progressively die. Currently, there is no cure for ALS, and patients typically live between 2 and 5 years after diagnosis. Now, in a new study published in Science Advances, researchers have shown how to leverage artificial intelligence (AI) to gain deeper insights into ALS progression. The study, led by researchers from the School of Psychology and Neuroscience at the University of St Andrews (Scotland, UK), in collaboration with the Department of Neuroscience, University of Copenhagen (Copenhagen, Denmark), found that certain neural circuits that control movement are compromised early in the disease, while others deteriorate later as the disease progresses. The techniques used in the study allow for the simultaneous analysis of multiple cell types within the spinal cord, enhanced by an innovative AI-driven analytical method. This enabled the identification of specific networks of ...
- Source: drugdu
- 66
- July 4, 2024
New AI-System Detects Breast Cancer with Almost 100% Accuracy

Breast cancer represents 30% of all new cancer diagnoses in women annually, with projections from the American Cancer Society indicating that 42,500 women will succumb to the disease in 2024. Researchers have now developed a new artificial intelligence (AI) architecture capable of detecting breast cancer with a remarkable 99.72% accuracy, demonstrating the potential to redefine digital pathology. This development follows a previous initiative by the same research team at Northeastern University (Boston, MA, USA) which launched a web-based AI application aimed at diagnosing prostate cancer more efficiently and accurately. These projects are part of a broader effort to establish an online platform that allows physicians to utilize advanced AI techniques for diagnosing various cancers. For the breast cancer project, the research team utilized the publicly accessible Breast Cancer Histopathological Database, which includes images of both malignant and benign breast tissues. Leveraging this resource, they built an ensemble deep learning model ...
- Source: drugdu
- 106
- June 29, 2024
Eli Lilly, OpenAI Strike Collaboration Agreement Seeking to Discover New Antimicrobials to Fight Drug-Resistant Bacteria

Don Tracy, Associate Editor The collaboration with OpenAI is part of Lilly’s strategy to combat drug-resistant pathogens through its Social Impact Venture Capital Portfolio. Eli Lilly and Company and OpenAI have agreed to terms on a deal to leverage generative artificial intelligence (AI) for discovering new antimicrobials to combat drug-resistant bacteria. According to Lilly, antimicrobial resistance (AMR) poses a significant risk throughout the world, especially in low- and middle-income countries. Additionally, the misuse and overuse of antimicrobials in humans, animals, and plants are the primary influences for developing drug-resistant pathogens, amplifying AMR in the process.1 “Our collaboration with OpenAI represents a groundbreaking step forward in the fight against the growing but overlooked threat of antimicrobial resistance,” said Diogo Rau, EVP, chief information and digital officer, Lilly, in a press release. “Generative AI opens a new opportunity to accelerate the discovery of novel antimicrobials and the development of custom, purpose-built technologies ...
- Source: drugdu
- 116
- June 29, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.